agile telehealth glp-1 Struggling with weight loss, cravings, or staying on track with nutrition? 👀 Our program now offers support to help you take control of your health and finally start seeing Agile - Yep, you read

Description

According to the SURMOUNT-1 clinical trial, patients using tirzepatide at the highest dose (15 mg weekly) experienced up to 22.5% total body weight loss over 72 weeksgreater than what is typically seen with semaglutide GLP-1

In a 64-week trial enrolling 307 overweight adults, oral semaglutide 25 mg once daily caused an average weight loss of 13.6% compared to 2.2% with placebo

A plateau may call for investigation and adjustment

Follow these simple steps: Stop using affected sites completely

Injectable Semaglutide Has the strongest clinical evidence for obesity treatment Produces greater average weight loss Delivers consistent drug levels due to reliable absorption This is why injectable semaglutide remains the gold standard for medical weight-loss programs